← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #919 OF 1,000 MOST-CITED

Master production and control records, procedure

FDA cited this observation 15 times across 15 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs15
BY FISCAL YEAR
FY20241
FY20235
FY20222
FY20202
FY20192
FY20183

How FDA worded it — real examples

The preparation of your master production and control records was not followed in accordance with your written procedure.

Genentech, Inc. · Hillsboro, Oregon · Drugs · 2024-04-19

The preparation of your master production and control records was not followed in accordance with your written procedure.

Vetio Animal Health ULC · Saint-Laurent · Drugs · 2023-08-18

The preparation of your master production and control records was not described in a written procedure and followed in accordance with your written procedure.

Sri Krishna Pharmaceuticals Limited · Hyderabad · Drugs · 2023-05-19

The preparation of your master production and control records was not followed in accordance with your written procedure.

Safecor Health, LLC · Woburn, Massachusetts · Drugs · 2023-03-16

The preparation of your master production and control records was not described in a written procedure.

MiMedx Group, Inc. · Kennesaw, Georgia · Drugs · 2023-03-02

The preparation of your master production and control records was not described in a written procedure.

Eurovet Animal Health B.V. · Bladel · Drugs · 2022-10-25

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →